PharmaCyte Biotech, Inc.
PMCB · NASDAQ
7/31/2025 | 4/30/2025 | 1/31/2025 | 10/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $2 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | -$1 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$8 | $13 | -$2 | -$0 |
| Pre-Tax Income | -$8 | $12 | -$3 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$8 | $12 | -$3 | -$1 |
| % Margin | – | – | – | – |
| EPS | -1.23 | 1.6 | -0.44 | -0.39 |
| % Growth | -176.9% | 463.6% | -12.8% | – |
| EPS Diluted | -1.23 | 1.6 | -0.44 | -0.39 |
| Weighted Avg Shares Out | 7 | 7 | 7 | 8 |
| Weighted Avg Shares Out Dil | 7 | 7 | 7 | 8 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$8 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |